Clinical Trial

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is to evaluate the effectiveness of treatment for esophagogastric junction carcinoma, total neoadjuvant therapy (TNT) including pembrolizumab and FLOT is conducted, aiming to choose between surgery or organ preservation treatment strategies.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-04; most recent amendment 2025-08-25.
Status change: Not Yet Recruiting → Recruiting 2025-07-23
Trial Details
NCT Number NCT07018570
Lead Sponsor National Cancer Center Hospital East
Collaborators: Merck Sharp & Dohme LLC
Conditions Gastroesophageal Junction (GEJ) Adenocarcinoma
Enrollment 26 participants
Start Date 2025-07-24
Primary Completion 2030-06 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-26